AzTrials
AzTrials

FPIESQUALIMNCT04643704

Quality of Life and Eating Disorders in Children With FPIES, Food Allergy or Celiac Disease

An observational study of FPIES and IgE Mediated Food Allergy, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Food allergies are associated with a decrease in quality of life. Patients with FPIES often have more food avoidance than necessary. The greater the number of avoided foods, the greater the risk of eating disorders. Read more about this study

Who is it for?
Ages Up to 12 yearsHealthy volunteers can take part
Conditions the study is for
FPIES, IgE Mediated Food Allergy, Celiac Disease
How many people
403 participants
Where
1 siteFrance
Study dates
5 Jan 2021to 22 Jul 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 12 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Study population: Patients recruited from hospitalization (conventional, and day-care unit) and consultation. Healthy controls without any food avoidance recruited from consultations, hospitalisations or community. Multicentric study * Pediatric Nutrition and Gastroenterology Unit - Trousseau Hospital, APHP; * Pediatric Pneumology and Allergy Unit - Necker-Enfants Malades Hospital, APHP; * Pediatric department and Asthma and Allergy unit - Ambroise Paré Hospital, APHP.

Who may be able to join

  • Any patient from 0 to 12 years of age, with FPIES or an IgE-mediated food allergy or celiac disease.
  • Controls: chid from 0 to 12 years old, without any food avoidance for medical reason, and without chronical severe pathology

Who cannot join

  • General exclusion criteria:
  • Families and patients who do not understand French
  • Cured food allergy (FPIES, IgE or non IgE-mediated food allergy)
  • Allergic patient (FPIES, IgE-mediated food allergy) undergoing oral or epicutaneous tolerance induction
  • Criteria for non-inclusion in the "FPIES" group:
  • Patient with mixed FPIES with associated IgE-mediated symptomatology
Show all 14Show fewer
  • Non IgE-mediated food allergies other than FPIES
  • Criteria for non-inclusion in the "celiac disease" group:
  • Patient with hypersensitivity to non-celiac gluten
  • Criteria for non-inclusion in the "control" group:
  • Current food avoidance, personal or in one of the household members due to allergy, or digestive disorders (abdominal pain, diarrhea for example) induced by the consumption of particular foods and requiring a strict avoidance diet
  • Chronic digestive pathology (chronic inflammatory bowel disease, functional bowel disorders with a correlation of symptoms with diet, esophagitis and eosinophilic enteropathy)
  • Chronic nutritional, metabolic or endocrine pathologies for which diet can have an impact: obesity, dyslipidemia, diabetes
  • Severe chronic respiratory pathology (eg: cystic fibrosis, chronic respiratory failure)

Trial locations and contacts

1 site in 1 country.

France1 site
  • Trousseau Hospital, Service : Nutrition et Gastroentérologie Pédiatrique

    Paris

Other trials in France

About this study

Official title: Evaluation of Quality of Life and Eating Disorders in Children With Food Protein Induced Enterocolitis Syndrom, Food Allergy or Celiac Disease

Food allergies are associated with a decrease in quality of life. Patients with FPIES often have more food avoidance than necessary. The greater the number of avoided foods, the greater the risk of eating disorders.

To date, no study about quality of life or assessment of eating difficulties has been performed in a French-speaking pediatric population with FPIES or celiac disease

Read the detailed description

1.1 Current state of knowledge

IgE-mediated food allergies are allergies whose symptoms are urticaria, angioedema, rhinoconjunctivitis, digestive signs, bronchospasm, or even anaphylaxis within 2 hours after ingestion of food. The prevalence of these food allergies in children ranges from 1.6% to 5.6%. Patients with food allergy should follow a strict avoidance diet of the culprit food, until tolerance get acquired in a few months or years later. The avoidance diet is set up by the parents, and must be applied in all places where the child lives (family, nursery and school). Careful reading of the labels and displays in collective restorations are essential in order to limit accidental ingestion. For the most ubiquitous and / or risky foods, parents often have to provide packed lunches. An IgE-mediated emergency kit is required, containing an antihistamine, and sometimes a self-injectable epinephrine pen and bronchodilators. The protocol in the event of an allergic reaction must be known by all caregivers for the child, in order to react immediately if necessary.

Food protein-induced enterocolitis syndrome or FPIES is one of the non IgE-mediated forms of food allergy. Incidence is estimated around 0.015-0.7% in infants and children. FPIES symptoms are delayed: vomiting within 1 to 4 hours after ingestion of the offending food, associated with other symptoms such as lethargy with pallor, diarrhea secondarily. Unlike other non IgE-mediated allergies, FPIES is a potentially severe allergy, with hypovolemic shock seen in 15-33% of cases with dehydration. The most frequently offending foods are ubiquitous, such as milk, fish, eggs, rice and oats. The management of patients with FPIES consists of the avoidance of the offending food(s) until that tolerance is acquired spontaneously in a few months or years. A specific first aid kit is also prescribed, in order to limit dehydration in the event of vomiting after an accident of ingestion, with at least oral rehydration solution.

Celiac disease is a gluten-induced autoimmune enteropathy responsible for digestive malabsorption. It affects 1.4% of the population in the world. The symptoms are very varied, such as chronic diarrhea or chronic constipation resistant to laxative treatment, abdominal distension, chronic fatigue, weight loss and growth retardation, nutritional deficiencies. The treatment consists of a lifelong elimination of gluten only (strict for wheat, rye, barley, and controlled for oats). To date, celiac disease is not curable, but the elimination diet allows clinical, biological and histological normalization in the digestive mucosa. Unlike FPIES or IgE-mediated allergies, the patient and their family do not have to fear a severe reaction in case of accidental exposure, and no first aid kit is required.

1.2 Description of the population to be studied and justification of their choice

FPIES and IgE-mediated food allergies primarily affect young children. A limiting factor in terms of age for this study is the fact that the Food Allergy Quality of Life Questionnaire (FAQLQ) has not been translated into French for adolescents over 12 years old.

The population studied is therefore children under 12 years of age, with a diagnosis of FPIES, IgE-mediated allergy or celiac disease. A control group is also planned to be included.

1.3 Description of the elements covered by the study

. Quality of Life

Food allergies negatively impact the quality of life of patients and their families due to prolonged and restrictive avoidance diet.

The quality of life of children with celiac disease does not differ from that of healthy children.

In our experience, parents of patients with FPIES often report fear of another impressive allergic reaction, with profuse vomiting, and a child described as lethargic and pale during the reaction.

Parents sometimes prefer to delay entering the community in the face of fear of accidental exposure to the culprit allergen, or the fear of a reaction with the introduction of new food, especially if the child is already allergic to several groups of food.

The quality of life of families is more impaired in cases of FPIES than in cases of IgE-mediated food allergy.

During childhood, there are 2 ways to assess the quality of life: a) by measuring the quality of life of the child himself, or b) by measuring the quality of life of the child according to the perception of parents.

The generic PedsQLTM quality of life questionnaire was validated in English and in French to assess children's quality of life, using a form to be completed by parents from birth and / or by the child after the age of 5.

Food allergy-specific quality of life questionnaires: FAQL-PB (Food Allergy Quality of Life-Parental Burden) and FAQLQ-PF (Food Allergy Quality of Life Questionnaire - Parent Form) have been validated for IgE-mediated food allergies and in FPIES in parents of children aged 0 to 12 in an English version. There is also a French version of FAQLQ-PF and FAQLQ-CF (Food Allergy Quality of Life Questionnaire - Child Form).

To date, no quality of life study has been performed in a French-speaking pediatric population with FPIES or celiac disease.

Eating disorders

Food neophobia is physiological between the ages of 2 and 6, but becomes pathologic if it persists beyond 6 years or if it is exacerbated between 2 and 6 years. It is defined by a refusal to eat foods which are new or not known by the child.

Although the majority of patients with FPIES are allergic to only one food, children's diets are often over-restricted to several food groups.

Eating disorders affect 22 to 50% of children with FPIES. These are mainly food refusals, swallowing or chewing difficulties, and sensory disturbance. The risk of food refusal is increased in the event of multiple-food FPIES. In a cohort of 32 patients, only half of these patients received a specialist opinion for the management of eating disorders, probably due to default screening for these disorders.

The French Child Food Rejection Scale (CFRS) score allows screening for food neophobia and pickiness in children aged 2 to 7.

For older children (over 7 years old) and adults, there is the Food Neophobia Scale (FNS), adapted in French (AFNS: Adapted Food Neophobia Scale).

To date, no study has evaluated eating disorders in a French-speaking pediatric population with FPIES or celiac disease.

1.4 Rationale for the duration of the study The research will last at least 2 years. The goal is to include at least 100 patients with FPIES, 100 patients with IgE-mediated food allergy other than FPIES, 100 patients with celiac disease and 100 control patients.

Keywords
Quality of life, Food avoidance, restriction, Food allergy, Feeding disorder, Psychology
Medical subject headings
Food Hypersensitivity, Celiac Disease, Feeding and Eating Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04643704
Study groupRoleWhat they receive
FPIES100 patients
IgE mediated food allergy100 patients
Celiac disease100 patients
Control group100 patients

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Quality of life (QoL) in children with FPIES

    FAQLQ (Food Allergy Quality of Life Questionnaire)-PF (Parent form) for parents of children from 0 to 12 years old with FPIES FAQLQ-CF (Child Form) for children between 8 to 12 years old with FPIES PedsQLTM: generic questionnaire of QoL for parents and children from 0 to 12 years old with FPIES

    Measured: 12 months

Secondary outcomes (7)
  1. Food neophobia in children with FPIES

    CFRS (Child Food Rejection Scale) for children with FPIES from 2 to 7 years old AFNS (Adapted Food Neophobia Scale) for children with FPIES from 8 to 12 years old

    Measured: 24 months

  2. QoL in children with food allergy

    FAQLQ-PF for parents of children from 0 to 12 years old with IgE-mediated food allergy FAQLQ-CF for children between 8 to 12 years old with IgE-mediated food allergy PedsQLTM: generic questionnaire of QoL for parents and children from 0 to 12 years old with IgE-mediated food allergy

    Measured: 24 months

  3. QoL in children with celiac disease

    : generic questionnaire of QoL for parents and children from 0 to 12 years old with IgE-mediated food allergy PedsQLTM child form: generic questionnaire of QoL for children from 5 to 12 years old

    Measured: 24 months

  4. QoL in children without any food avoidance

    PedsQLTM: generic questionnaire of QoL for parents and children from 0 to 12 years old with IgE-mediated food allergy PedsQLTM child form: generic questionnaire of QoL for children from 5 to 12 years old

    Measured: 24 months

  5. Food neophobia in children with food allergy

    CFRS (Child Food Rejection Scale) for children from 2 to 7 years old AFNS (Adapted Food Neophobia Scale) for children from 8 to 12 years old

    Measured: 24 months

  6. Food neophobia in children with celiac disease

    CFRS (Child Food Rejection Scale) for children from 2 to 7 years old AFNS (Adapted Food Neophobia Scale) for children from 8 to 12 years old

    Measured: 24 months

  7. Food neophobia in children without any food avoidance

    CFRS (Child Food Rejection Scale) for children from 2 to 7 years old AFNS (Adapted Food Neophobia Scale) for children from 8 to 12 years old

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Nov 2020
  2. Study start5 Jan 2021
  3. Primary completion22 Jul 2022
  4. Study completion22 Jul 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
403 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04643704
Sponsor's protocol ID
APHP201063
Other IDs
IDRCB 2020-A02017-32
Acronym
QUALIM
Status last verified
Sep 2022
First submitted
19 Nov 2020
Last updated
28 Sep 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of FPIES and IgE Mediated Food Allergy, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Quality of life (QoL) in children with FPIES (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in